Orexin-B

Orexin-B is one of the two orexin neuropeptides, the counterpart to orexin-A, and is also called hypocretin-2 ^[1][3]. Both peptides are carved from a single precursor, prepro-orexin, produced by neurons in the hypothalamus ^[1]. Orexin-B is a linear peptide of 28 amino acids and, unlike orexin-A, contains no disulfide bonds; this simpler structure and its receptor preferences set it apart from the folded, 33-residue orexin-A ^[1][3].

Like orexin-A, orexin-B is synthesized by a small cluster of neurons in the lateral and posterior hypothalamus that project widely across the brain ^[1]. These neurons excite the brain's arousal centers, and the two orexin peptides act together as the output of this system, helping to sustain wakefulness and to coordinate feeding, energy balance, and related functions ^[2]. The system was identified in 1998 by two groups working independently, which is why the peptides carry two names, orexins and hypocretins ^[3].

A key difference between the two orexins is receptor selectivity: while orexin-A activates both orexin receptors about equally, orexin-B acts mainly at the orexin type 2 receptor (OX2R) and is considerably weaker at the type 1 receptor ^[3]. Because the type 2 receptor is especially tied to the control of sleep and wakefulness, orexin-B and OX2R have drawn particular attention in sleep research ^[3]. As with the orexin system generally, the peptides' role in stabilizing arousal is highlighted by narcolepsy, in which loss of the orexin-producing neurons removes this signal ^[2][4].

Interest in orexin-B centers largely on its favored receptor. Orexin receptor antagonists, some of which block the type 2 receptor, are used to treat insomnia, and orexin receptor agonists that stimulate these receptors are in development for narcolepsy and excessive daytime sleepiness ^[3]. Orexin-B itself is primarily an endogenous signaling molecule and a research peptide rather than a marketed medicine, and it is widely used in the laboratory to study orexin receptor function ^[1][3].

There is essentially no human safety data; what exists is preclinical. As an arousal peptide the sensible cautions mirror orexin-A: overstimulation, disrupted sleep if timed late, and poorly characterized effects overall. Treat it as a research and reference compound, not something to dose casually.

Orexin-B, also called hypocretin-2, was identified in 1998 alongside orexin-A in the same landmark discoveries by the groups of Takeshi Sakurai and Masashi Yanagisawa, who named the orexins for their appetite-stimulating effects, and Luis de Lecea and Gregor Sutcliffe, who called the peptides hypocretins. It is a 28-amino-acid neuropeptide cut from the same precursor protein, prepro-orexin, as orexin-A but lacking the internal disulfide bonds of its sibling, and it is produced by the same population of lateral hypothalamic neurons.

Research quickly established that orexin-B activates the orexin-2 receptor strongly while engaging the orexin-1 receptor far more weakly, a selectivity that helped disentangle the roles of the two receptors in feeding, arousal, and sleep. As the orexin system was revealed to be central to the stability of wakefulness, orexin-B and its preferred receptor became important reference points for the development of the dual orexin receptor antagonists that now treat insomnia. The peptide continues to serve as a key tool in orexin pharmacology.

Orexin-B is best appreciated as an essential piece of the orexin system, the arousal network whose discovery reshaped sleep medicine, and its receptor preference has proved especially instructive. Because it activates the orexin-2 receptor so much more strongly than the orexin-1 receptor, it helped researchers pin the type-2 receptor as the principal driver of sleep-wake control, knowledge that underpins the modern insomnia drugs suvorexant, lemborexant, and daridorexant, which work by blocking the very signaling whose loss produces narcolepsy, making insomnia and narcolepsy pharmacological mirror images.

That conceptual symmetry is one of the more elegant stories in neuropharmacology. As with other neuropeptides, orexin-B itself is used chiefly as a research and investigational agent rather than a medicine, given the delivery challenges peptides face, and much of the therapeutic action has moved to small molecules acting at its receptors. Its contribution to understanding how the brain gates sleep and wakefulness, however, remains substantial and enduring.